Advancing rare disease trials by overcoming patient recruitment challenges
Next month, clinical development and clinical operations professionals will gather and discuss the current challenges in running clinical trials for…
All articles by Irena Maragkou
Irena Maragkou
Irena Maragkou is a Healthcare Researcher for Clinical Trials Arena and Pharmaceutical Technology based in London, UK. Irena previously worked in consulting at Deloitte’s Strategy, M&A and Analytics Department, focusing on projects in the Pharmaceutical and Healthcare Sector. She holds an MSci degree in Neuroscience from UCL.
-
-
IRA holds the scope to shape pharma’s research strategy, say experts
Pharma companies will need to rethink business and research and development (R&D) strategies to mitigate against the global impact that…
-
European agencies catch up with speedier regulatory pathways for CGTs in the US
Although the regulatory landscape for advanced therapy medicinal products (ATMPs) is rapidly evolving, varying regulatory requirements across different regions are…
-
Investment surges, hurdles and emerging innovations in neuroscience
Innovation in neuropsychiatry has been dormant for nearly forty years, said Kabir Nath, CEO, Compass Pathways in a panel discussion…
-
CPHI Europe: how AI can drive growth in the nutraceutical space
“Consumer demands drive flexible and optimised manufacturing processes and also infrastructure,”said Catarina Abreu, Head of Nutraceuticals at PIPA AI. At…
-
CPHI Europe: strategies to navigate nitrosamines risk evaluation
Drug impurities such as nitrosamines can often contaminate drugs leading to recalls and regulatory actions given their carcinogenic nature. These…
-
Cell and gene therapy approvals drive paradigm change in manufacturing
Innovative cell and gene therapies (CGTs) have significantly disrupted the treatment landscape for several genetic diseases. In recent years, the…
-
CPHI Europe: Targeting supply chain bottlenecks key for cell and gene therapies
Cell therapies stand at the frontier of medicine and hold the potential to potentially cure diseases, said Angela Vollstedt, global…
-
CPHI Europe: Overcoming the unique challenges with high-concentration mAbs
There is an increasing number of high-concentration mAbs among approved therapeutics, with 76% of US Food and Drug Administration (FDA)-approved mAbs…
-
CPHI Europe: Gummies as a drug delivery system could improve compliance
Gummies have become the second best-selling delivery model in all of vitamins, mineral and supplements (VMS) space, said Mitchell Slade,…